The IASLC Latin America Conference on Lung Cancer 2019 (LALCA 2019) provides a unique opportunity for participants to attend lectures by international and national speakers on key advances in the science of treating, detecting and preventing lung cancer and other thoracic malignancies.

In addition to its main scientific program, LALCA 2019 will host several special workshops and forums. For example, due to tobacco being a dominant cause of lung cancer mortality, LALCA will host the Cancer Control Program and Tobacco Forum, scheduled for Thursday, October 17. Additionally, the IASLC School of Oncology will once again offer an intense workshop for young researchers, clinicians and trainee physicians from different disciplines - including medical oncology, thoracic surgery, radiation oncology, pulmonary, radiology and pathology. And finally, the successful Round Table  discussions will continue in 2019, providing delegates the unique opportunity to discuss specific topics directly with international leaders and local experts.

Live Activity Date: October 17-19, 2019

Physicians, surgeons, medical oncologists, pulmonologists, pathologists, radiation oncologists, epidemiologists, basic researchers, nurses,  advocates and anyone interested in thoracic oncology are encouraged to attend this event.

Upon completion of this activity, the participants should be able to: 

• Apply evidence-based recommendations and clinical practice guidelines to diagnose and treat patients with lung cancer and other thoracic malignancies. 
• Describe scientific advances in lung cancer and other thoracic malignancies. 
• Synthesize research from clinical trials and translational studies to deepen knowledge within primary specialty area(s) and broaden knowledge of other specialties.

Program Co-Chairs: 

• Oscar Arrieta, MD, Instituto Nacional de Cancerlogia de Mexico, Mexico City, Mexico
• Saul Campos, MD, Centro Oncologico Estatal ISSEMYM, Mexico City, Mexico
• Fernando Aldaco, MD, Oncologo Medico, Centro Medico Nacional, Mexico City, Mexico
• Jaime De La  Garza, MD, Instituto Nacional de Cancerlogia de Mexico, Mexico City, Mexico
• Luis Raez, MD, Florida Internatinoal Unversity, Miami, FL, USA
• Christian Rolfo, MD, Icahn School of Medicine at Mount Sinai, New York, NY, USA
• Edgardo Santos, MD, The Oncology Institute of Hope and Innovation, Boca Raton, FL, USA

The information presented is that of the contributing faculty and does not necessarily represent the views of the International Association for the Study of Lung Cancer and/or any named commercial entity providing financial support. Specific therapies discussed may not be approved and/or specified for use as indicated by the faculty presenters. Therefore, before prescribing any medication, please review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse effects.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities

If you need assistance with this activity, please email: education@iaslc.org.